Glycogen synthase kinase 3: A drug target for CNS therapies

Journal of Neurochemistry

Volumn 89, Issue 6, 2004, Pages 1313-1317

  Bhat, Ratan V ^a   Budd Haeberlein, Samantha L ^a   Avila, Jesús ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Alzheimer's disease; Bipolar disorder; Phosphorylation; Schizophrenia; Signal transduction; Tau kinase

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; ADENOSINE TRIPHOSPHATE; ANILINOMALEIMIDE; AR A014418; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDIRUBIN; LITHIUM; MALEIMIDE DERIVATIVE; PAULLONE; TAU PROTEIN; THIADIAZOLE DERIVATIVE; THIADIAZOLIDINONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; COGNITION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; MOOD DISORDER; NERVE CELL NECROSIS; NEURITE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; STROKE;

ALZHEIMER DISEASE; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INSULIN RESISTANCE; LITHIUM; NEURONAL PLASTICITY; NEURONS; PHOSPHORYLATION;

EID: 3042558276     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02422.x     Document Type: Short Survey

References (45)

1. Beals C. R., Sheridan C. M., Turck C. W., Gardner P. and Crabtree G. R. (1997) Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275, 1930-1934.
2. Bhat R. V., Shanley J., Correll M. P., Fieles W. E., Keith R. A., Scott C. W. and Lee C. M. (2000) Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl Acad. Sci. USA 97, 11074-11079.
3. Bhat R. V., Leonov S., Luthman J., Scott C. W. and Lee C.-M. (2002) Interactions between GSK3β and caspase signaling pathways during NGF deprivation induced cell death. J. Alzheimer's Dis. 4, 291-301.
4. Bhat R. V., Xue Y., Berg S. et al. (2003) Structural insights and biological effects of Glycogen synthase kinase 3 specific inhibitor AR-A014418. J. Biol. Chem. 278, 45937-45945.
5. Braak E., Braak H. and Mandelkow E. M. (1994) A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 87, 554-567.
6. Bullock B. P. and Habener J. F. (1998) Phosphorylation of the cAMP response element binding protein CREB by cAMP-dependent protein kinase A and glycogen synthase kinase-3 alters DNA-binding affinity, conformation, and increases net charge. Biochemistry 37, 3795-3809.
7. Cross D. A., Culbert A. A., Chalmers K. A., Facci L., Skaper S. D. and Reith A. D. (2001) Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. 77, 94-102.
8. Doble B. W. and Woodgett J. R. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175-1186.
9. Eldar-Finkelman H. (2002) Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 8, 126-132.
10. Ewing F. M., Deary I. J., McCrimmon R. J., Strachan M. W. and Frier B. M. (1998) Effect of acute hypoglycemia on visual information processing in adults with type 1 diabetes mellitus. Physiol. Behav. 64, 653-660.
11. Frame S., Cohen P. and Biondi R. M. (2001) A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7, 1321-1327.
12. Gould T. D., Gray N. A. and Manji H. K. (2003) Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacol. Res. 48, 49-53.
13. Grace E. A. and Busciglio J. (2003) Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. J. Neurosci. 23, 493-502.
14. Grimes C. A. and Jope R. S. (2001) CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J. Neurochem. 78, 1219-1232.
15. Hanger D. P., Betts J. C., Loviny T. L., Blackstock W. P. and Anderton B. H. (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 71, 2465-2476.
16. Hetman M., Cavanaugh J. E., Kimelman D. and Xia Z. (2000) Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J. Neurosci. 20, 2567-2574.
17. Hiesberger T., Trommsdorff M., Howell B. W., Goffinet A., Mumby M. C., Cooper J. A. and Herz J. (1999) Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron 24, 481-489.
18. Hughes K., Nikolakaki E., Plyte S. E., Totty N. F. and Woodgett J. R. (1993) Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J. 12, 803-808.
19. Ishigaro K., Shiratsuchi A., Sato S., Omori A., Arioka M., Kobayashi S., Uchida T. and Imahori K. (1993) Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 325, 167-172.
20. Jackson G. R., Wiedau-Pazos M., Sang T. K., Wagle N., Brown C. A., Massachi S. and Geschwind D. H. (2002) Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34, 509-519.
21. Johnson C. D., Puntis M., Davidson N., Todd S. and Bryce R. (2001) Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma. Br. J. Surg. 88, 662-668.
22. Kaytor M. D. and Orr H. T. (2002) The GSK3beta signalling cascade and neurodegenerative disease. Curr. Opin. Neurobiol. 12, 275-278.
23. Klein P. S. and Melton D. A. (1996) A molecular mechanism for the effect of lithium on development. Proc. Natl Acad. Sci. USA 93, 8455-8459.
24. Kosik K. S. (1992) Alzheimer's disease: a cell biological perspective. Science 256, 780-778.
25. Kratz J. E., Steams D., Huso D. L., Slunt H. H., Price D. L., Borchelt D. R. and Eberhart C. G. (2002) Expression of stabilized beta-catenin in differentiated neurons of transgenic mice does not result in tumor formation. BMC Cancer 2, 33.
26. Leclerc S., Gamier M., Hoessel R. et al. (2001) Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease: a property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276, 251-260.
27. Leost M., Schultz C., Link A. et al. (2000) Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267, 5983-5894.
28. Leroy K., Boutajangout A., Authelet M., Woodgett J. R., Anderton B. H. and Brion J. P. (2002) The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol. 103, 91-99.
29. Liu J., Stevens J., Rote C. A., Yost H. J., Hu Y., Neufeld K. L., White R. L. and Matsunami N. (2001) Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol. Cell 7, 927-936.
30. Lucas J. J., Hernandez F., Gomez-Ramos P., Moran M. A., Hen R. and Avila J. (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20, 27-39.
31. Martinek S., Inonog S., Manoukian A. S. and Young M. W. (2001) A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 105, 769-779.
32. Martinez A., Alonso M., Castro A., Pérez C. and Moreno F. J. (2002a) First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 45, 1292-1299.
33. Martinez A., Castro A., Dorronsoro I. and Alonso M. (2002b) Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Rev. 22, 373-384.
34. Morfini G., Pigino G., Beffert U., Busciglio J. and Brady S. T. (2002) Fast axonal transport misregulation and Alzheimer's disease. Neuromol. Med. 2, 89-99.
35. Nikoulina S. E., Ciaraldi T. P., Mudaliar S., Mohideen P., Carter L. and Henry R. R. (2000) Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 49, 263-271.
36. Osbome J. E. (2002) Loss of beta-catenin expression is associated with disease progression in malignant melanoma. Br J. Dermatol. 146, 1104.
37. Pei J. J., Tanaka T., Tung Y. C., Braak E., Iqbal K. and Grundke-Iqbal I. (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56, 70-78.
38. Pérez M., Hernandez F., Gomez-Ramos A., Smith M., Perry G. and Avila J. (2002a) Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur. J. Biochem. 269, 1484-1489.
39. Phiel C. J., Wilson C. A., Lee V. M. and Klein P. S. (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439.
40. Sheldon M., Rice D. S., D'Arcangelo G., Yoneshima H., Nakajima K., Mikoshiba K., Howell B. W., Cooper J. A., Goldowitz D. and Curran T. (1997) Scrambler and yotari disrupt the disabled gene and produce a reeler-like phenotype in mice. Nature 389, 730-733.
41. Smith D. G., Buffet M., Fenwick A. E., Haigh D., Ife R. J., Saunders M., Slingsby B. P., Stacey R. and Ward R. W. (2001) 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 11, 635-639.
42. Spittaels K., Van den Haute C., Van Dorpe J. et al. (2000) Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 275, 41340-41390.
43. Takashima A., Noguchi K., Michel G., Mercken M., Hoshi M., Ishiguro K. and Imahori K. (1996) Exposure of rat hippocampal neurons to a-myloid beta peptide (25-35) induces the inactivation ofphosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci. Lett. 203, 33-36.
44. Woodgett J. R. (1991) cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol. 200, 564-577.
45. Zheng-Fischhofer Q., Biemat J., Mandelkow E. M., Illenberger S., Godemann R. and Mandelkow E. (1998) Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical- filament-like conformation. Eur. J. Biochem. 252, 542-552.